<DOC>
	<DOCNO>NCT00818480</DOCNO>
	<brief_summary>This protocol open subject previously enrol complete Phase I Phase II study administer YM155 . Subjects receive benefit treatment YM155 eligible complete previous study .</brief_summary>
	<brief_title>An Extension Study Administering YM155 Subjects Previously Enrolled Another Protocol Administering YM155</brief_title>
	<detailed_description>The main objective study continue evaluate safety efficacy YM155 . Each subject treat dose he/she receive completion his/her previous phase I phase II YM155 study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Completed Phase I II YM155 study least stable disease continue meet criterion state previous YM155 study allow additional treatment YM155 Lack progression base recent radiological imaging , biochemical assessment and/or physical examination Negative pregnancy test result ( female childbearing potential ) More 21 day ( 14 day depend study origin ) time last infusion YM155 stop previous study propose start first infusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>prostate cancer</keyword>
	<keyword>melanoma</keyword>
	<keyword>lymphoma</keyword>
	<keyword>YM155</keyword>
</DOC>